Intravenous ketamine and intranasal esketamine were shown to improve symptoms of depression among adults, researchers reported in JAMA Psychiatry.
“The most important finding of our study is that both esketamine and [intravenous] ketamine can help alleviate symptoms in patients suffering from treatment-resistant depression, as long as they are provided in an evidence-based manner and with rigorous clinical standards,” Sina Nikayin, MD, assistant professor of psychology at Yale University School of Medicine, told Healio.
Of the 210 patients included in the analysis, 126 (61.4%)